PF-Atlas › Clinical Trials › NCT02846324
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
GBT440 · Phase 2
Registry ID
NCT02846324
Phase
Phase 2
Status
Completed
Drug / intervention
GBT440
Sponsor
Global Blood Therapeutics
Start
2016-06
Enrollment
39
Locations
12
About this trial
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02846324 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.